1 Effects of an imidazo-pyridine (zolpidem: 10, 20 and 30 mg) on overnight sleep and on performance the next day were studied in young adults and in middle aged individuals. The young adults were used particularly as an homogenous group to establish any possible adverse effects of the drug on sleep and on performance the next day, and the middle aged subjects with their less restful sleep were used to study efficacy. 2 In the young adults zolpidem led to a marked increase in slow wave sleep with a reduction in stage 2 sleep. There were no significant changes in REM sleep, though there was a tendency for REM sleep to be delayed. 3 In the middle aged there was a reduction in awake activity and drowsy sleep with an increase in stage 2 sleep. The latency to REM sleep was increased but the duration of REM sleep over the whole night was not reduced. 4 Digit symbol substitution and a complex reaction time task were used to study performance, but there were no residual effects with zolpidem (9 h after ingestion). 5 Zolpidem is likely to prove useful in the management of transient and short-term insomnia in healthy middle aged individuals when impaired performance the next day is to be avoided.
Introduction
Over the past few years the development of hypnotics has led to drugs free of residual effects the next day, and of accumulation on daily ingestion. These are usually referred to as being rapidly eliminated, but their mean elimination half-lives vary between 2 and 5 h, and it may be more appropriate to consider them in two categories, those which are ultra-rapidly eliminated with half-lives of around 2-3 h (q.v. Nicholson & Rudzik, 1981; Amrein et al., 1983) and those which are rapidly eliminated with half-lives of around 4-5 h (q.v. Nicholson et al., 1983a,b) .
The distinction between ultra-rapid and rapid elimination may well have clinical relevance. A drug which is ultra-rapidly eliminated has a very short duration of action and would be ideal for sleep onset insomnia, but to reduce nocturnal awakenings throughout the night a relatively high dose may have to be given. This may suppress unduly the central nervous system during the early part of the night, and may lead to anterograde amnesia (Roehrs et al., 1983 ), a pronounced decrease in rapid eye movement sleep and respiratory depression. As far as anterograde amnesia and respiratory depression are concerned these could be of significance in the use of hypnotics by the elderly, and anterograde amnesia would be relevant to individuals involved in skilled activity.
On the other hand, less rapidly eliminated hypnotics with half-lives of around 5 h, whilst still free of residual effects and of accumulation on daily ingestion, would be more likely to sustain sleep and reduce awakenings over the night (Nicholson, 1983) . Unnecessarily high doses would not be needed, and adverse effects Correspondence: Dr A. N. Nicholson, RAF Institute of Aviation Medicine, Farnborough, Hampshire, UK during the early part of the night would be avoided. It is with these considerations in mind that we have studied an imidazo-pyridine (zolpidem, SL80 0750-23N; Figure 1 ) which is adequately absorbed and has a mean elimination half-life of between 3.5 and 5.1 (mean 4.0) h (Synthelabointernal report). Experiments were carried out in two groups of subjects. Studies in a homogenous group of young adults were carried out to identify any possible adverse effects of the drug on sleep and on performance the next day, and healthy middle aged individuals with less restful sleep were used to establish the efficacy of the compound.
Methods
Twelve healthy male volunteers in two age groups of six were studied. Six were aged between 18-23 (mean 20.9) years and six were aged between 45-52 (mean 48.1) years. They were required to avoid napping and undue exercise, and to abstain from alcohol and caffeine during the day preceding an experimental night. The subjects were familiar with the laboratory and sleep recording techniques. Two adaptation nights when placebos were ingested preceded each study, and then each subject received 10 mg diazepam, 10, 20 and 30 mg zolpidem, and two further placebos. For each group of subjects the treatments were arranged in a pseudo-random order based on a Latin square where two of the six treatments were placebo. All medication was identical in appearance, and the study was double-blind with a week separating each inges-H3C t/~~~~~~~~~C H3, 2 H H3C 0 Ho N C-tion. Capsules were taken under supervision at 'lights out' (23.00-23.30 h) which was fixed for each subject.
The subjects reported to the laboratory 1.5 h before bedtime. They slept in individual lightproofed, sound-attenuated and temperature (18 ± 1°C) and humidity (55 ± 1%) controlled bedrooms. In an adjoining room three channels of electroencephalographic (EEG) activity were recorded (C4-A1, PI-T5 and OzPz-03), together with bilateral electro-oculograms and the submental electromyogram using a paper speed of 10 mm s-4. The subjects were woken, if necessary, at the same time each week (07.00-07.30 h).
Each sleep record was scored independently into 30s epochs by two analysts according to conventional criteria, and differences in the annotation of sleep stages (which did not occur in more than 5% of the epochs) were resolved.
Subjective assessments of sleep and wellbeing were measured using visual analogue scales. Half an hour after awakening each subject completed four assessments. The assessments and extremes of the 100 mm scales were: A: I slept, very poorly-very well; B: Now I feel, very sleepywide awake; C: I fell asleep, never immediately; D: After I fell asleep, I slept, very badlyvery well. In each case a favourable response tended toward the 100 extreme of the scale. The residual effects of the medication were tested 9 h after ingestion using digit symbol substitution (Nicholson & Stone, 1982 ) and a complex reaction time task (Pascoe & Stone, 1984) . Before the experiment began the subjects were trained until they had reached steady performance. The sleep, subjective assessments and performance data were analysed separately for each group of subjects using analysis of variance (ANOVA) for a randomised blocks design with subjects as blocks and drugs as treatments. The assumptions of ANOVAhomogeneity of variance, normality and additivity were studied by considering transformations of the raw measures using the maximum likelihood method of Box & Cox (1964) . The residuals from an analysis of variance applied to data using the selected transformation were then examined after the method of Anscombe (1961) , and if appropriate this transformation was applied. Many of the transformations for sleep measures were logarithmic, and so random variation and treatment effects were proportional rather than additive. Means for raw data are presented in the tables, although this occasionally leads to apparent minor inconsistencies with the results of the analysis. If no satisfactory transformation could be determined Friedman's non-parametric analysis of variance was used.
After analysis of variance two planned comparisons between means (for six subjects) were made, i.e. between the two placebos, and between the mean of the two placebos and diazepam. Each of the remaining treatments was compared with the mean of the two placebos using the multiple comparison method of Dunnett (1964) . The test of each of these hypotheses was made with a specified size a posteriori, and so no account was taken of the composite F test for differences between treatments. The different components of the error term which applied to each group of comparisons were tested for homogeneity using Bartlett's test.
Results
The results are given in Tables 1-8. In both groups of subjects diazepam (10 mg) reduced the number of awakenings (P < 0.01) and the durations of awake activity (P < 0.01) and stage 1 (drowsy) sleep (middle aged: P < 0.05; young adults: P < 0.01). In the middle aged total sleep time and the sleep efficiency index were increased (P < 0.01) Diazepam increased the duration of stage 2 sleep in both groups (middle aged: P < 0.01; young adults: P < 0.001), and in the young adults there was a reduction in the duration of stage 4 sleep (P < 0.05). Significance levels: * P < 0.05; ** P < 0.01. Significance levels: * P < 0.05; ** P < 0.01. Significance levels: * P < 0.05; ** P < 0.01; *** P < 0.001 Significance levels: * P < 0.05; ** P < 0.01. Significance levels: * P < 0.05; ** P < 0.01; *** P < 0.001. Significance levels: * P < 0.05; ** P < 0.01. Significance level: * P < 0.05.
In the middle aged subjects zolpidem (10, 20 and 30 mg) reduced the duration of awake activity (P < 0.05, P < 0.01, P < 0.01, respectively), and there were fewer awakenings (P < 0.01) with 20 and 30 mg. The highest dose also decreased stage 1 (drowsy) sleep (P < 0.05) and increased stage 2 sleep (P < 0.01). Latencies to rapid eye movement (REM) sleep were longer (P < 0.01) with 20 and 30 mg, but the duration of REM sleep and the REM/NREM ratio were not significantly altered.
Zolpidem did not change awake activity or stage 1 (drowsy) sleep in the young adults. The highest dose decreased the duration of stage 2 sleep (P < 0.05), and there was an increase in stage 3 sleep (P < 0.01). Slow wave sleep (stages 3 and 4) was increased with 20 and 30 mg (P < 0.01). There were no significant changes in REM sleep with zolpidem although latencies to REM sleep did appear to be longer.
Both groups of subjects reported that they slept better with diazepam (young adults: P < 0.05; middle aged: P < 0.001), and the middle aged subjects felt that they fell asleep more quickly (P < 0.01). Subjective assessments were not altered with zolpidem in the young adults, but the middle aged considered that their sleep was improved by all doses (P < 0.01), and that 20 and 30 mg hastened sleep onset (P < 0.05). Subjects did not report any residual effects with either diazepam or zolpidem, and performance 9 h after ingestion was not impaired (Table 9 ).
Discussion
Zolpidem provides useful hypnotic activity over a dose range which would appear to be free of residual effects on performance. In the middleaged, awake activity and the number of awakenings were reduced, and the subjects reported improved sleep over the night without subjective sequelae. Decreased wakefulness was accompanied by decreased drowsy sleep, and by a dose-related increase of stage 2. The effect was similar to that of diazepam, except that there was no increase in total sleep time with 10 and 20 mg and only a possibility of an increase with 30 mg. There was a delay to the mean onset of the first period of rapid eye movement (REM) sleep, though there was no significant reduction in the duration of REM activity.
In the young adults the effect of zolpidem on sleep differed from that of diazepam. There was a marked increase in slow wave sleep, and with each dose of zolpidem slow wave sleep was greater than that with 10 mg diazepam. The predominant effect of diazepam in young adults was a decrease in wakefulness and drowsy sleep with an increase in stage 2 sleep, whereas with zolpidem there was increased slow wave activity with a reduction in stage 2 sleep. An increase in slow wave sleep with an hypnotic has been observed, though to a lesser extent, with the cyclopyrrolone, zopiclone (Nicholson & Stone, 1983) . The phenomenon raises the question whether the normal evolution of the stages of non-REM sleep during the night can be modulated by drugs which influence the GABAergic system in a similar but not identical way to benzodiazepines used as hypnotics. Indeed, zopiclone has high affinity for the central benzodiazepine receptor but, unlike diazepam, does not recognise peripheral sites in the kidney (Blanchard et al., 1983) . Further, both zolpidem and zopiclone are free of monoaminergic and histaminergic activity (Laboratories d'Etudes et de Recherches Synthelabo -Internal Report, Blanchard et al., 1983) , and so their differential effects may well arise from an individual interaction with the benzodiazepine receptor, though facilitation of GABAergic transmission may not be the common pathway subsequent to occupation of the receptor (Weber et al., 1985) .
The clinical relevance of the increase in slow wave sleep with zolpidem in young adults is uncertain. However, it would appear that slow wave sleep is only increased when a significant part of sleep is occupied normally by slow wave activity. The mean duration (min) of slow wave sleep in the young adults observed in the present study was 45.7 (9.7%), and this increased to 62.3 (13.2%), 81.4 (17.3%) and 78.8 (17.0%) for the three doses. On the other hand, in the middle aged subjects there was only 6.3 min (1.3%) of slow wave sleep and no increase was observed.
The profile of zolpidem as an hypnotic is, therefore, of interest. In middle aged subjects it sustains sleep throughout the night over a dose range free of residual effects, whereas in young adults it leads to an increase in slow wave sleep. These studies would suggest that zolpidem is a promising hypnotic for the management of transient and short term insomniaparticularly in the middle aged with their less restful sleep and those involved in skilled activity when impaired performance the next day must be avoided.
